Search


 
Results 21 - 30 of about 252 for "Highlights".

Approved drugs for diabetic neuropathy better than placebo ...

In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants ...

Newer glucose-lowering drugs associated with lower mortality ...

Researchers compared Swedish patients with type 2 diabetes who were new users of dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter ...

Pioglitazone, but not rosiglitazone, associated with increased ...

The results of this study pose the question of whether the increased likelihood of bladder cancer, which is rare, justifies withholding pioglitazone from ...

Incretin-based drugs not associated with greater heart failure ...

Researchers compared patients taking dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues to those taking 2 or ...

Insulin pumps for type 1 diabetes associated with lower ...

Insulin pump users had lower cardiovascular mortality than similar patients with type 1 diabetes who injected their own insulin, a study found.

Risk for poor outcomes appears higher in diabetic patients ...

Patients with diabetes who have lacunar stroke are at higher risk for death and recurrent stroke than patients without diabetes, according to a recent ...

Intensive therapy associated with decreases in certain ...

Despite the ACCORD study finding an increased risk of death from cardiovascular causes with intensive glucose-lowering therapy, rates of ...

Thiazolidinedione add-ons associated with less CV risk, study ...

The UK-based retrospective cohort study used a database that linked national hospitalization and mortality data for people who were prescribed second ...

Socioeconomic status appears linked to mortality in patients ...

The study looked at data from the Sweden National Diabetes Register to determine what patient characteristics were related to all-cause mortality or ...

Cardiovascular event rates similar between once-weekly ...

A limitation of the industry-funded randomized trial was the high rate of early discontinuation: 43.0% of patients on exenatide and 45.2% of those on placebo ...

Result Page: < Previous  1 2 3 4 5 6 7  Next >